Genmab A/S: Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)

Nineteen abstracts accepted, including multiple presentations on the safety and efficacy of investigational epcoritamab (DuoBody-CD3xCD20) in a variety of treatment settings and hematologic malignancies

Related Keywords

Netherlands ,Cairo ,Al Qahirah ,Egypt ,Louisiana ,United States ,Japan ,New Orleans ,Tokyo ,Denmark ,Copenhagen ,Køavn ,New Jersey ,Oostindie ,Groningen ,American ,David Freundel ,Epcoritamab Monotherapy ,Judith Klimovsky ,Andrew Carlsen ,Rituximab Lenalidomide ,Exposition Of The American Society Hematology ,Product Communications ,Macrophage Propertiesj Immunol ,Twitter ,Ernestn Morial Convention Center ,American Society Of Hematology ,Exchange Commission ,Health Care Resource Utilization ,Development Of Novel Anti ,Company Announcement ,Annual Meeting ,American Society ,Convention Center ,Executive Vice President ,Chief Development Officer ,Yearly Results ,Refractory Diffuse Largeb Cell Lymphoma Eligible ,Autologous Stem Cell Transplant ,Updated Phase ,Refractory Follicular Lymphoma ,First Line Treatment ,Follicular Lymphoma ,Initial Results ,Novel Subgroup Analyses ,Largeb Cell Lymphoma ,Lymphoma Symptoms ,Health Related Quality ,Refractory Largeb Cell Lymphoma Treated ,Subcutaneous Epcoritamab Dose Expansion ,Patients With Relapsed ,Refractory Largeb Cell ,Non Hodgkin Lymphomas ,Newly Diagnosed Patients ,Refractory Aggressive Matureb Cell ,Rituximab Combination ,Preclinical Models ,Subcutaneous Epcoritamab ,Combination With Rituximab ,Epcoritamab Among Patients With Relapsed ,Evaluate Safety ,Outpatient Setting Among Patients With Relapsed ,Refractory Diffuse Grade ,Largeb Cell ,Novel Combinations ,Anti Neoplastic Agents ,Non Hodgkin Lymphoma ,Dose Escalation Results From ,First In Human Phase ,With Relapsed ,Multiple Myeloma ,World Outcomes ,Refractory Diffuse Largeb Cell Lymphoma Treated ,Patients With Follicular Lymphoma Receiving ,Real World Evaluation ,Care Resource Utilization ,Patients With Largeb Cell Lymphoma ,Annual Report ,Media Release ,Y Shaped Genmab ,Clinically Utilized ,Directed Antibodies ,Macrophage Properties ,Novel Anti Cd ,Cell Surface ,Cancer Sci ,Investor Relations ,Vice President ,Genmab ,Nnounces ,Multiple ,Abstracts ,Resented ,4th ,Nnual ,Meeting ,Exposition ,Society ,Hematology ,